Evidence map›Paper›PMID 26590448›Full record

ReviewAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2016

Role of the Gut Microbiome in Uremia: A Potential Therapeutic Target.

Ali Ramezani, Ziad A Massy, Björn Meijers, Pieter Evenepoel, Raymond Vanholder, Dominic S Raj

4 registry-linked trialsOpen access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 236 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
236citing papers in PubMed, 7 pooled it
14.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04204005 nacompletednot on this mapstarted 2017, after this paper: background citation

Probiotics-addicted Low-protein Diet for Microbiota Modulation in Patients With Advanced Chronic Kidney Disease (ProLowCKD): a Protocol of Placebo-controlled Randomized Trial

TypeinterventionalSponsorProbiotical S.p.A.Ran2017 to 2020Enrolled50ConditionsRenal Failure ChronicArmsProbiotics
NCT04361097 nacompletednot on this mapstarted 2018, after this paper: background citation

Fecal Microbiota Transplantation as a Therapeutic Strategy in the Progression of Chronic Kidney Disease

TypeinterventionalSponsorHospital Universitario Dr. Jose E. GonzalezRan2018 to 2020Enrolled28ConditionsChronic Kidney Disease Due to Hypertension, Chronic Kidney Disease Due to Type 2 Diabetes MellitusArmsFaecal microbiota transplant, Placebo
NCT04527640 naunknown statusnot on this mapstarted 2020, after this paper: background citation

Effects of Synbiotics Supplementation on the Concentration of the Uremic Toxin Indoxyl Sulfate, Symptoms of Constipation, and Constipation-related Quality of Life in End-stage Renal Disease Patients Undergoing Hemodialysis

TypeinterventionalSponsorIndonesia UniversityRan2020 to 2021Enrolled60ConditionsConstipation, End Stage Renal Disease on DialysisArmsSynbiotics containing Lactobacillus acidophilus & Bifidobacterium longum 5x10^9 CFU and FOS 60 mg, Placebo
NCT04689074 completednot on this mapstarted 2021, after this paper: background citation

Costituzione Della Biobanca Del Microbiota Intestinale e Salivare Umano: Dalla Disbiosi Alla Simbiosi

TypeobservationalSponsorAzienda Ospedaliero-Universitaria Consorziale Policlinico di BariRan2021 to 2022Enrolled150ConditionsAutosomal Dominant Polycystic Kidney Disease (ADPKD), Advanced-Chronic Kidney Disease (CKD), Diabetic Kidney Disease (DKD), IgA Nephropathy (IgAN)ArmsBiological sample collection, Questionnaire, Medical examination
3 · Its place in the literature

Who cites it

236 citing papers in PubMed, 7 syntheses or guidelines pooled it, 382 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Effect of Dietary Inulin Supplementation on the Gut Microbiota Composition and Derived Metabolites of Individuals Undergoing Hemodialysis: A Pilot Study.Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation · 2021
    Trial
  16. Trial
  17. Trial
  18. Trial
  19. A Bibliometric Analysis of Publications in Uremic Toxins From 1991 to 2024.Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy · 2026
    Review
  20. Review

176 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 3 countries.

Ali RamezaniDivision of Renal Diseases and Hypertension, The George Washington University, Washington, DC.
Ziad A MassyDivision of Nephrology, Ambroise Paré University Hospital, Assistance Publique-Hôpitaux de Paris, University of Paris Ouest-ersailles-Saint-Quentin-en-Yvelines (UVSQ), Boulogne-Billancourt/Paris, France; INSERM U1018, Research Centre in Epidemiology and Population Health (CESP) Team 5, University of Paris Ouest-Versailles-Saint-Quentin-en-Yvelines (UVSQ), Villejuif, France.
Björn MeijersDivision of Nephrology, Department of Microbiology and Immunology, University Hospitals Leuven, Leuven, Belgium.
Pieter EvenepoelDivision of Nephrology, Department of Microbiology and Immunology, University Hospitals Leuven, Leuven, Belgium.
Raymond VanholderNephrology Section, Department of Internal Medicine, University Hospital, Ghent, Belgium.
Dominic S RajDivision of Renal Diseases and Hypertension, The George Washington University, Washington, DC. Electronic address: draj@mfa.gwu.edu.
George Washington University · USKU Leuven · BEGhent University Hospital · BEUniversité de Versailles Saint-Quentin-en-Yvelines · FR

Funding

Cytokine Gene Polymorphism in CRIC CohortR01DK073665 · NIDDK · UNIVERSITY OF NEW MEXICO · PI RAJ, DOMINIC S · 2006 to 2010
$2.3M
Gut Microbiota and Atherosclerosis in ESRDU01DK099914 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI RAJ, DOMINIC S · 2013 to 2017
$1.9M
Anti-inflammatory Therapy in Diabetic CKDU01DK099924 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI RAJ, DOMINIC S · 2013 to 2018
$1.8M
NIDDK NIH HHS 1R01DK073665-01A1NIDDK NIH HHS 1U01DK099914-01NIDDK NIH HHS 1U01DK099924-01NIDDK NIH HHS R01 DK073665NIDDK NIH HHS U01 DK099914NIDDK NIH HHS U01 DK099924
6 · The paper itself

Abstract

Also known as the "second human genome," the gut microbiome plays important roles in both the maintenance of health and the pathogenesis of disease. The symbiotic relationship between host and microbiome is disturbed due to the proliferation of dysbiotic bacteria in patients with chronic kidney disease (CKD). Fermentation of protein and amino acids by gut bacteria generates excess amounts of potentially toxic compounds such as ammonia, amines, thiols, phenols, and indoles, but the generation of short-chain fatty acids is reduced. Impaired intestinal barrier function in patients with CKD permits translocation of gut-derived uremic toxins into the systemic circulation, contributing to the progression of CKD, cardiovascular disease, insulin resistance, and protein-energy wasting. The field of microbiome research is still nascent, but is evolving rapidly. Establishing symbiosis to treat uremic syndrome is a novel concept, but if proved effective, it will have a significant impact on the management of patients with CKD.

Indexed as

DysbiosisRenal Insufficiency, ChronicDisease ProgressionEarly Medical InterventionGastrointestinal MicrobiomeHumansUremiaamineammoniachronic kidney disease (CKD)end-stage renal disease (ESRD)Gut microbiomeindolemetabolomemicrobial metabolitep-cresyl sulfate (PCS)phenolreviewthiolureauremic syndromeuremic toxin

Identifiers

PMID26590448
PMCPMC5408507
OpenAlexW2180350916

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.